Pricing

Samaritan Pharmaceuticals, Inc. (SPHC)

followers ·
Sector: HEALTH CARE
Industry: HEALTH CARE
SIC: SERVICES-BUSINESS SERVICES, NEC

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

    Formally known as:
  • Samaritan Pharmaceuticals Inc.
Stock Split History
DateRatio
2007-07-05 1:6
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Samaritan Pharmaceuticals, Inc. (Samaritan) is an entrepreneurial biopharmaceutical company, focused on commercializing therapeutic products to relieve the suffering of patients with Alzheimer's disease, cancer, cardiovascular disease, human immunodeficiency virus (HIV), and Hepatitis C. Samaritan also focuses on commercializing its acquired marketing and sales rights to sell 15 marketed revenue-generating products, in Greece, and/or various Eastern European countries. The Company has partnered its oral entry inhibitor HIV drug SP-01A, a drug that has demonstrated safety and efficacy, in Phase II clinical trials, with Pharmaplaz, Ireland to advance to Phase III clinical trials. In addition, it aims to commercialize three market drug candidates with late-stage preclinical development programs. On March 1, 2007, Samaritan completed its acquisition of Metastatin Pharmaceuticals.
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available